
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
The Oncology Institute Inc. has demonstrated significant revenue growth, achieving year-over-year increases of 24%, 28%, and 21% from 2022 to 2024, coinciding with an expansion in the number of clinics under management from 67 to 86. The overall oncology market in the U.S. is substantial, exceeding $200 billion, with projections indicating a continued rise in oncology drug expenditures at a compound annual growth rate (CAGR) of over 10%. With anticipated strong growth in key markets like Nevada and Florida, alongside robust dispensing revenue and margin expansion due to better utilization of existing capacity, the outlook for the company remains favorable.
Bears say
The Oncology Institute Inc. has recently experienced a significant decline in revenue contribution from HUM, dropping from 20% to less than 10%, raising concerns about its financial stability. Additionally, investor apprehensions regarding cash levels nearing the $40 million minimum covenant threshold have placed downward pressure on TOI's stock in 4Q24. Lastly, the company's anticipated revenue trends appear to be well below the industry average, potentially creating further headwinds for growth in 2026 and 2027.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares